Vertex Pharmaceuticals Inc. closed $108.22 short of its 52-week high ($519.88), which the company achieved on November 8th.
Analyst Evan Seigerman of BMO Capital maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report), retaining the price target of ...
International Assets Investment Management LLC lowered its position in shares of Vertex Pharmaceuticals Incorporated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback